ChloroquineV1, Main, Exploration, bibRecord, 002C28

Low-dose methotrexate in rheumatic diseases—Efficacy, side effects, and risk factors for side effects

Identifieur interne : 002C28 ( Main/Exploration ); précédent : 002C27; suivant : 002C29

Low-dose methotrexate in rheumatic diseases—Efficacy, side effects, and risk factors for side effects

Auteurs : Armin Schnabel ; Wolfgang L. Gross

Source :

Seminars in Arthritis and Rheumatism [ 0049-0172 ] ; 1994.

RBID : ISTEX:B81F07C499C8BB30EFD835D353A9D9C45013534C

English descriptors

Teeft :
- Arthriti, Arthritis, Arthritis rheum, Case reports, Clinical experience, Cohort, Concomitant medications, Cumulative dose, Cutaneous, Cutaneous vasculitis, Discontinuation, Dos, Dose methotrexate, Folic, Folic acid, Folinic, Folinic acid, Hematologic, Hepatic, Hepatic toxicity, Histological, Histological liver damage, Limited number, Liver biopsies, Liver histology, Methotrexate, Methotrexate pneumonitis, Methotrexate therapy, Methotrexate treatment, Mgiwk, Nodulosis, Observational studies, Other agents, Parenteral gold, Placebo, Pneumonitis, Progression, Prospective study, Psoriasis, Psoriatic, Psoriatic patients, Radiologic progression, Radiological progression, Randomized, Renal, Retrospective analysis, Rheum, Rheumatic diseases, Rheumatoid, Rheumatoid arthritis, Rheumatoid arthritis patients, Rheumatoid vasculitis, Rheumatol, Risk factors, Secondary failure, Side effects, Significant improvement, Small number, Suppl, Supplementation, Syndrome, Systemic manifestations, Temporary discontinuation, Therapeutic effect, Toxicity, Vasculitis, Weinblatt.

Abstract

Abstract: Controlled trials and observational studies have shown low-dose methotrexate (MTX) to be a second-line agent of high potency with a favorable profile of safety and tolerability in the treatment of rheumatoid arthritis (RA). Its riskbenefit ratio in psoriatic arthritis is less well documented. Preliminary reports on its beneficial effects in other disorders, including the systemic manifestations of RA, other spondyloarthritides, and collagen vascular diseases, merit more detailed examination. Gastrointestinal intolerance and hepatic enzyme elevation are the most frequent side effects of MTX; life-threatening events such as severe hemocytopenia and MTX pneumonitis are rare and amenable to prevention by recognizing risk factors and premonitory signs. Hepatotoxicity does not appear to be a major limiting factor in RA patients over the first 2 to 3 years of MTX therapy; its impact on long-term tolerance remains to be clarified.

Url:

https://api.istex.fr/ark:/67375/6H6-4MK12KLG-G/fulltext.pdf

DOI: 10.1016/0049-0172(94)90027-2

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 001364
to stream Istex, to step Curation: 001364
to stream Istex, to step Checkpoint: 001A13
to stream Main, to step Merge: 002C88
to stream Main, to step Curation: 002C28

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Low-dose methotrexate in rheumatic diseases—Efficacy, side effects, and risk factors for side effects</title>
<author><name sortKey="Schnabel, Armin" sort="Schnabel, Armin" uniqKey="Schnabel A" first="Armin" last="Schnabel">Armin Schnabel</name>
</author>
<author><name sortKey="Gross, Wolfgang L" sort="Gross, Wolfgang L" uniqKey="Gross W" first="Wolfgang L." last="Gross">Wolfgang L. Gross</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:B81F07C499C8BB30EFD835D353A9D9C45013534C</idno>
<date when="1994" year="1994">1994</date>
<idno type="doi">10.1016/0049-0172(94)90027-2</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-4MK12KLG-G/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001364</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001364</idno>
<idno type="wicri:Area/Istex/Curation">001364</idno>
<idno type="wicri:Area/Istex/Checkpoint">001A13</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001A13</idno>
<idno type="wicri:doubleKey">0049-0172:1994:Schnabel A:low:dose:methotrexate</idno>
<idno type="wicri:Area/Main/Merge">002C88</idno>
<idno type="wicri:Area/Main/Curation">002C28</idno>
<idno type="wicri:Area/Main/Exploration">002C28</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Low-dose methotrexate in rheumatic diseases—Efficacy, side effects, and risk factors for side effects</title>
<author><name sortKey="Schnabel, Armin" sort="Schnabel, Armin" uniqKey="Schnabel A" first="Armin" last="Schnabel">Armin Schnabel</name>
</author>
<author><name sortKey="Gross, Wolfgang L" sort="Gross, Wolfgang L" uniqKey="Gross W" first="Wolfgang L." last="Gross">Wolfgang L. Gross</name>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Seminars in Arthritis and Rheumatism</title>
<title level="j" type="abbrev">YSARH</title>
<idno type="ISSN">0049-0172</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1994">1994</date>
<biblScope unit="volume">23</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="310">310</biblScope>
<biblScope unit="page" to="327">327</biblScope>
</imprint>
<idno type="ISSN">0049-0172</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0049-0172</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Arthriti</term>
<term>Arthritis</term>
<term>Arthritis rheum</term>
<term>Case reports</term>
<term>Clinical experience</term>
<term>Cohort</term>
<term>Concomitant medications</term>
<term>Cumulative dose</term>
<term>Cutaneous</term>
<term>Cutaneous vasculitis</term>
<term>Discontinuation</term>
<term>Dos</term>
<term>Dose methotrexate</term>
<term>Folic</term>
<term>Folic acid</term>
<term>Folinic</term>
<term>Folinic acid</term>
<term>Hematologic</term>
<term>Hepatic</term>
<term>Hepatic toxicity</term>
<term>Histological</term>
<term>Histological liver damage</term>
<term>Limited number</term>
<term>Liver biopsies</term>
<term>Liver histology</term>
<term>Methotrexate</term>
<term>Methotrexate pneumonitis</term>
<term>Methotrexate therapy</term>
<term>Methotrexate treatment</term>
<term>Mgiwk</term>
<term>Nodulosis</term>
<term>Observational studies</term>
<term>Other agents</term>
<term>Parenteral gold</term>
<term>Placebo</term>
<term>Pneumonitis</term>
<term>Progression</term>
<term>Prospective study</term>
<term>Psoriasis</term>
<term>Psoriatic</term>
<term>Psoriatic patients</term>
<term>Radiologic progression</term>
<term>Radiological progression</term>
<term>Randomized</term>
<term>Renal</term>
<term>Retrospective analysis</term>
<term>Rheum</term>
<term>Rheumatic diseases</term>
<term>Rheumatoid</term>
<term>Rheumatoid arthritis</term>
<term>Rheumatoid arthritis patients</term>
<term>Rheumatoid vasculitis</term>
<term>Rheumatol</term>
<term>Risk factors</term>
<term>Secondary failure</term>
<term>Side effects</term>
<term>Significant improvement</term>
<term>Small number</term>
<term>Suppl</term>
<term>Supplementation</term>
<term>Syndrome</term>
<term>Systemic manifestations</term>
<term>Temporary discontinuation</term>
<term>Therapeutic effect</term>
<term>Toxicity</term>
<term>Vasculitis</term>
<term>Weinblatt</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: Controlled trials and observational studies have shown low-dose methotrexate (MTX) to be a second-line agent of high potency with a favorable profile of safety and tolerability in the treatment of rheumatoid arthritis (RA). Its riskbenefit ratio in psoriatic arthritis is less well documented. Preliminary reports on its beneficial effects in other disorders, including the systemic manifestations of RA, other spondyloarthritides, and collagen vascular diseases, merit more detailed examination. Gastrointestinal intolerance and hepatic enzyme elevation are the most frequent side effects of MTX; life-threatening events such as severe hemocytopenia and MTX pneumonitis are rare and amenable to prevention by recognizing risk factors and premonitory signs. Hepatotoxicity does not appear to be a major limiting factor in RA patients over the first 2 to 3 years of MTX therapy; its impact on long-term tolerance remains to be clarified.</div>
</front>
</TEI>
<affiliations><list></list>
<tree><noCountry><name sortKey="Gross, Wolfgang L" sort="Gross, Wolfgang L" uniqKey="Gross W" first="Wolfgang L." last="Gross">Wolfgang L. Gross</name>
<name sortKey="Schnabel, Armin" sort="Schnabel, Armin" uniqKey="Schnabel A" first="Armin" last="Schnabel">Armin Schnabel</name>
</noCountry>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C28 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002C28 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:B81F07C499C8BB30EFD835D353A9D9C45013534C
   |texte=   Low-dose methotrexate in rheumatic diseases—Efficacy, side effects, and risk factors for side effects
}}

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021

	Serveur d'exploration Chloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration Chloroquine

Low-dose methotrexate in rheumatic diseases—Efficacy, side effects, and risk factors for side effects

Low-dose methotrexate in rheumatic diseases—Efficacy, side effects, and risk factors for side effects

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri